{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.763","upperLimit":"0.910","value":"0.837"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"102"}],"units":"Participants"}],"description":"Event-free Survival was defined as time from study entry to death from any cause, disease progression or recurrence, or second malignant neoplasm. Event-free survival was estimated by KM estimate.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients will receive 6 cycles of Induction chemotherapy consisting of carboplatin and etoposide (Cycles 1, 3, and 5) alternating with ifosfamide and etoposide (Cycles 2, 4, and 6). The entire length of Induction is 18 weeks unless delay occurs due to myelosuppression or unanticipated toxicity. Each cycle of Induction will begin when ANC \\> 750/L and platelets \\> 75,000/L and when off filgrastim (G-CSF) for at least 48 hours. Following the Induction phase (weeks 0-18) those patient in CR will undergo radiation therapy.\n\ncarboplatin: Given IV\n\netoposide: Given IV\n\nifosfamide: Given IV\n\nthiotepa: Given IV\n\nadjuvant therapy\n\nconventional surgery\n\nneoadjuvant therapy\n\nperipheral blood stem cell transplantation\n\nradiation therapy: craniospinal irradiation","id":"OG000","title":"Radiation Therapy (CR From Induction)"}],"paramType":"NUMBER","populationDescription":"Two ineligible patients were excluded. A total of 102 eligible patients were analyzed.","reportingStatus":"POSTED","timeFrame":"At 3 years from study entry","title":"The Probability of Event-free Survival (EFS)","type":"SECONDARY","unitOfMeasure":"Probability"}